Analysis of epidemiological indicators of parathyroid gland diseases in the Chuvash republic based on registry data

RELEVANCE. Primary hyperparathyroidism is one of the most common endocrine diseases characterized by impaired calcium-phosphorus metabolism due to hypersecretion of parathyroid hormone.

GOAL. Assessment of the epidemiological situation with parathyroid gland diseases in the Chuvash Republic based on data from the All-Russian Registry of Patients with primary hyperparathyroidism. To analyze the data of patients with primary hyperparathyroidism in a retrospective cohort study from 2014 to 2025 at the clinical base of the Republican Clinical Hospital for War Veterans of the Ministry of Health of Chuvashia.

MATERIALS AND METHODS. The data on the Chuvash Republic from the All-Russian Registry of patients with primary hyperparathyroidism are analyzed. In the course of a retrospective cohort study (2014–2025), a cohort of patients registered at the Republican Clinical Hospital for War Veterans of the Ministry of Health of Chuvashia was analyzed. For statistical data processing, a descriptive method was used with the calculation of absolute and relative values (percentages).

RESULTS. It was found that the prevalence of parathyroid gland pathology in the region is 73.4 cases per 100,000 population. Key epidemiological features were identified: a pronounced predominance of women (88.9%) in the older age group, an uneven geographical distribution with a concentration of cases in urbanized areas (Cheboksary, Novocheboksarsk), as well as a significant increase in detection in recent years. The data obtained indicate the influence of both organizational factors (availability of specialized care) and possible environmental risks (imbalance of trace elements in water sources) on the prevalence of pathology.

CONCLUSION. The implemented electronic registry has proven its effectiveness for monitoring morbidity, planning medical care and conducting scientific research, which determines the prospects for its further development to optimize the system of endocrinological care in the region.

1. Mokrysheva NG, Kovaleva EV, Eremkina AK. Registries of parathyroid glands diseases in the Russian Federation. Problems of Endocrinology. 2021;67(4):4-7. (In Russ.) doi: https://doi.org/10.14341/probl12803

2. Sell J, Ramirez S, Partin M. Parathyroid Disorders. Am Fam Physician. 2022;105(3):289-298

3. Bandeira F, de Moura Nóbrega J, de Oliveira LB, Bilezikian J. Medical management of primary hyperparathyroidism. Arch Endocrinol Metab. 2022;66(5):689-693. doi: https://doi.org/10.20945/2359-3997000000558.

4. Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016;2:16033–16033. doi: https://doi.org/10.1038/nrdp.2016.33

5. Pigarova EA, Rozhinskaya LYa, Belaya JE, Dzeranova LK, Karonova TL, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.) doi: https://doi.org/10.14341/probl201662460-84

6. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561–3569. doi: https://doi.org/10.1210/jc.2014-1413

7. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16(1):33–39. doi: https://doi.org/10.1016/j.jocd.2012.12.001

8. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168–178. doi: https://doi.org/10.1016/S0140-6736(17)31430-7

9. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3580–3594. doi: https://doi.org/10.1210/jc.2014-1415

10. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, et al. International Workshop on Primary Hyperparathyroidism. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293-2314. doi: https://doi.org/10.1002/jbmr.467777

11. Мокрышева Н.Г., Мирная С.С., Добрева Е.А. и др. Первичный гиперпаратиреоз в России по данным регистра. Проблемы Эндокринологии. 2019;65(5):300-310.

12. Hedman A, Nilsson M, Lundgren E,et al. The Swedish National Quality Register for Primary Hyperparathyroidism.Läkartidningen. 2023;120:2365 doi: https://doi.org/10.14341/probl10126

13. Nilsson M. Impact of Surgery for Primary Hyperparathyroidism. [Doctoral Thesis (compilation), Department of Clinical Sciences, Lund]. LundUniversity, FacultyofMedicine. 2023. 215 c.

14. Айзетуллова Г.Р., Осипов В.Ф., Кузнецова Е.Г., Огурцов А.А. Влияние окружающей среды: соотношения микроэлементов как фактор развития первичного гиперпаратиреоза в Чувашской Республике. 2025. – Международный журнал прикладных и фундаментальных исследований. № 1 – С. 11-15. doi: https://doi.org/10.17513/mjpfi.13685

15. Avdeeva VA, Suplotova LA, Tarasenko VV, Nikulin MO. Clinical and laboratory features of primary hyperparathyroidism in Tyumen region: retrospective data of a three-year follow-up. Osteoporosis and Bone Diseases. 2023;26(1):24-30. (InRuss.) doi: https://doi.org/10.14341/osteo13124